Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer

Radiotherapy and Oncology

Volumn 105, Issue 2, 2012, Pages 184-192

  Denham, James W ^a   Wilcox, Chantelle ^a   Lamb, David S ^b   Spry, Nigel A ^c   Duchesne, Gillian ^d   Atkinson, Chris ^e   Matthews, John ^f   Turner, Sandra ^g   Kenny, Lizbeth ^h   Tai, Keen Hun ^d   Gogna, Nirdosh Kumar ⁱ   Ebert, Martin ^c   Delahunt, Brett ^j   McElduff, Patrick ^a   Joseph, David ^c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b WELLINGTON HOSPITAL   (New Zealand)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e St Georges Cancer Care Centre   (New Zealand)

^f AUCKLAND CITY HOSPITAL   (New Zealand)

^g WESTMEAD HOSPITAL   (Australia)

^h ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

ⁱ PRINCESS ALEXANDRA HOSPITAL   (Australia)

^j UNIVERSITY OF OTAGO   (New Zealand)

more..

Author keywords

Androgen suppression; Dose escalation; High dose rate brachytherapy boost; Prostate cancer; Rectal symptoms; Urinary symptoms

Indexed keywords

LEUPRORELIN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ADVANCED CANCER; AGED; ANTIANDROGEN THERAPY; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE ESCALATION; RANDOMIZED CONTROLLED TRIAL; RECTUM DISEASE; SYMPTOMATOLOGY; TREATMENT DURATION; URINARY TRACT DISEASE;

BRACHYTHERAPY; FOLLOW-UP STUDIES; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RECTUM; TUMOR BURDEN; URINATION DISORDERS;

EID: 84871297601     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2012.09.018     Document Type: Article

References (39)

1. T. Granfors, H. Modig, J.-E. Damber, and R. Tomic Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone J Urol 176 2006 544 547
2. M.V. Pilepich, K. Winter, and C. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290
3. M.V. Pilepich, K. Winter, and M.J. John Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252
4. A.V. D'Amico, M.-H. Chen, A.A. Renshaw, M. Loffredo, and P.W. Kantoff Androgen suppression and radiation vs radiation alone for prostate cancer JAMA 299 2008 289 295
5. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 2002 103 108
6. J.W. Denham, A. Steigler, and D.S. Lamb Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial Lancet Oncol 6 2005 841 850
7. M. Bolla, T.M. De Reijke, and G. van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
8. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
9. S.J. Freedland, J. Eastham, and N. Shore Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer Prostate Cancer Prostatic Dis 12 2009 333 338
10. S.B. Strum, J.E. McDermed, M.C. Scholz, H. Johnson, and G. Tisman Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade Br J Urol 79 1997 933 941
11. D.A. Galvao, D.R. Taaffe, N. Spry, D. Joseph, D. Turner, and R.U. Newton Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation Prostate Cancer Prostatic Dis 12 2009 198 203
12. V.B. Shahinian, Y.F. Kuo, J.L. Freeman, and J.S. Goodwin Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 2005 154 164
13. M. Braga-Basaria, A.S. Dobs, and D.C. Muller Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy J Clin Oncol 24 2006 3979 3983
14. J.W. Denham, A. Steigler, and D.S. Lamb Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial Lancet Oncol 12 2011 451 459
15. M.V. Lee, E.M. Fong, F.R. Singer, and R.S. Guenette Bisphosphonate treatment inhibits the growth of prostate cancer cells Cancer Res 61 2001 2602 2608
16. H.L. Neville-Webbe, I. Holen, and R.E. Coleman The anti-tumour activity of bisphosphonates Cancer Treat Rev 28 2002 305 319
17. S. Boissier, S. Magnetto, and L. Frappart Bisphosphates inhibit prostate and breast carcinoma cell adhesion to unmineralised and mineralised bone extracellular matrices Cancer Res 57 1997 3890 3894
18. F. Saad, D.M. Gleason, and R. Murray A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
19. TROG 03.04 RADAR trial-randomised androgen deprivation and radiotherapy, < http://clinicaltrials.gov/ct/show/NCT00193856?order=5 >; 2005.
20. A. Haworth, R. Kearvell, and P.B. Greer Assuring high quality treatment delivery in clinical trials-results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 "RADAR" set-up accuracy study Radiother Oncol 90 2009 299 306
21. Denham JW, Nowitz M, Joseph D, et al. Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the TROG 03.04 RADAR trial for locally advanced prostate cancer. University of Newcastle; 2012. Unpublished.
22. Denham JW, Wilcox C, Joseph D, et al. Quality of life in the TROG 03.04 RADAR randomised controlled trial for locally advanced prostate cancer. Lancet Oncol, in press.
23. M.A. Ebert, K.M. Harrison, and D. Cornes Comprehensive Australasian multicentre dosimetric intercomparison: issues, logistics and recommendations J Med Imaging Radiat Oncol 53 2009 119 131
24. M.A. Ebert, K.M. Harrison, and S.J. Howlett Dosimetric intercomparison for multicentre clinical trials using a patient-based anatomic pelvic phantom Med Phys 38 2011 5167 5175
25. K.M. Harrison, M.A. Ebert, and T. Kron Design, manufacture, and evaluation of an anthropomorphic pelvic phantom purpose-built for radiotherapy dosimetric intercomparison Med Phys 38 2011 5330 5337
26. M.A. Ebert, A. Haworth, and R. Kearvell Detailed review and analysis of complex radiotherapy clinical trial planning data: evaluation and initial experience with the SWAN software system Radiother Oncol 86 2008 200 210
27. LENT SOMA scales for all anatomic sites Int J Radiat Oncol Biol Phys 31 1995 1049 1091
28. M.A. Ebert, A. Haworth, and R. Kearvell Comparison of DVH data from multiple radiotherapy treatment planning systems Phys Med Biol 55 2010 N337 N346
29. D.R.H. Christie, J.W. Denham, and A. Steigler Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation Radiother Oncol 77 2005 117 125
30. C. Fiorino, G. Fellin, and T. Rancati Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: Preliminary results of a multicenter prospective study Int J Radiat Oncol Biol Phys 70 2008 1130 1137
31. S.L. Gulliford, K. Foo, and R.C. Morgan Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397 Int J Radiat Oncol Biol Phys 76 2010 747 754
32. A. Capp, M. Inostroza-Ponta, and D. Bill Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial Radiother Oncol 90 2008 400 407
33. J. Andreyev Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients Lancet Oncol 8 2007 1007 1017
34. H.J. Andreyev, S.E. Davidson, C. Gillespie, W.H. Allum, and E. Swarbrick Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer Gut 61 2012 179 192
35. D.S. Lamb, J.W. Denham, and D. Joseph A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial Int J Radiat Oncol Biol Phys 79 2011 385 391
36. J.A. Hatton, P.B. Greer, and C. Tang Does the planning dose-volume histogram represent treatment doses in image-guided prostate radiation therapy? Assessment with cone-beam computerised tomography scans Radiother Oncol 98 2011 162 168
37. L. Sullivan, S.G. Williams, K.-H. Tai, F. Foroudi, L. Cleeve, and G.M. Duchesne Urethral stricture following high dose rate brachytherapy for prostate cancer Radiat Oncol 91 2009 232 236
38. Zamboglou N, Tselis N, Baltas D, et al. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: Treatment evaluation and mature results. Int J Radiat Oncol Biol Phys, in press.
39. Singh J, Greer PB, White MA, et al. Treatment related morbidity in prostate cancer: a comparison of 3DCRT with and without image guidance using implanted fiducial markers. Int J Radiat Oncol Biol Phys, http://dx.doi.org/10. 1016/j.ijrobp.2012.07.2376.